From ASH Meeting on Hematologic Malignancies: How would you treat relapsed/refractory myeloma after transplant?
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: What are the approved options for relapsed marginal...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: How would you treat this patient with high-grade...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: What is the prognosis for symptomatic, bulky FL...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: How would you use molecular diagnostic tests to...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
From ASH Meeting on Hematologic Malignancies: How would you treat MDS that has not...
During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...
Studies Examine Link Between Ibrutinib and Atrial Fibrillation in Patients With Leukemia and Lymphoma
Though drug ibrutinib has been linked to the development of atrial fibrillation (AF) and atrial flutter (AFl), with an observed incidence of AF among...
Current Issue
November 2019 Bonus ASH Annual Meeting Preview Edition (Volume 5, Issue...
This issue offers an inside look at this year’s annual meeting, advice for giving effective presentations, and more.
